NDT Advance Access originally published online on November 4, 2007
Nephrology Dialysis Transplantation 2008 23(2):573-579; doi:10.1093/ndt/gfm731
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease
Department of Nephrology and Hypertension, University of Erlangen-Nuernberg, Nuernberg, Germany
Correspondence and offprint requests to: Dr. Raoul Zeltner, Medizinische Klinik 4, Universität Erlangen-Nuernberg, Breslauer Strasse 201, D-90471 Nuernberg, Germany. Tel: +49-911-398-2702; Fax: +49-911-398-3183; E-mail: raoul.zeltner{at}klinikum-nuernberg.de
 |
Abstract |
|---|
Background. Hypertension is a common complication in autosomal dominant polycystic kidney disease (ADPKD). This prospective randomized double-blind study was performed to compare the renal and cardiac effects of the ACE inhibitor ramipril and the β-blocker metoprolol as first line therapy in ADPKD patients with hypertension.
Methods. Forty-six hypertensive ADPKD patients were randomized to either ramipril (n = 23) or metoprolol (n = 23). Twenty-four hour (24-h) ambulatory blood pressure (BP), glomerular filtration rate (GFR) as calculated by the Cockcroft and Gault formula, urinary albumin excretion (albumin/creatinine ratio), and left ventricular mass index (LVMI) were established at baseline and at yearly intervals. The total follow-up was 3 years. Baseline characteristics were similar in both groups.
Results. Mean arterial pressure (MAP) decreased significantly in both the ramipril and the metoprolol group (–8 ± 2 and –6 ± 2 mmHg; both P < 0.01). There was a significant decline in renal function during follow-up which was similar in patients treated with ramipril or metoprolol (–2.5 ± 0.7 vs –2.9 ± 0.8 ml/min/year; P = NS). After the 3 years follow-up, no differences in GFR, LVMI and urinary albumin excretion were observed between the ramipril and the metoprolol group (80.7 ± 10.7 vs 78.0 ± 7.6 ml/min, 102.6 ± 6.8 vs 100.3 ± 5.4 g/m2; and 42.6 ± 12.3 vs 70.3 ± 32.5 mg/g, respectively; all P = NS). A post-hoc analysis evaluating the effects of BP control, revealed that LVMI increased in patients with standard BP control while it remained stable in patients with rigorous BP control with a significant difference in LVMI between the groups after 3 years of follow-up (110.5 ± 6.3 vs 90.9 ± 4.7 g/m2; P = 0.017). Also, by the end of the study albuminuria was lower in patients with rigorous vs standard BP control (23.5 ± 6.7 vs 94.8 ± 35.4 mg/g; P = 0.05).
Conclusions. In our study population of hypertensive ADPKD patients, no differences in renal function, urinary albumin excretion and LVMI were detected between those treated with ramipril or metoprolol, respectively, during a 3 years follow-up. Rigorous BP control prevented an increase in LVMI and reduced urinary albumin excretion, suggesting a crucial role of BP control for slowing progression of cardiac and renal organ damage in ADPKD.
Keywords: autosomal dominant polycystic kidney disease; hypertension; left ventricular hypertrophy; progression of renal disease
Received for publication: 22. 8.06
Accepted in revised form: 18. 9.07
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in NDT:
- Renal and cardiac effects of antihypertensive treatment with ramipril versus metoprolol in autosomal dominant polycystic kidney disease
- Theodore I. Steinman
NDT 2008 23: 431-433.[Extract] [FREE Full Text] - In this issue ...
NDT 2008 23: i.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  J. J. Grantham Autosomal Dominant Polycystic Kidney Disease N. Engl. J. Med., October 2, 2008; 359(14): 1477 - 1485. [Full Text] [PDF]
|
|